SHIKARI® Q-ATI

Enzyme immunoassay for the quantitative determination of specific antibodies to infliximab in human serum and plasma with confirmation.

Infliximab (Remicade) was associated to the development of anti-Infliximab antibodies,
even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remicade®. This might lead to severe complications.
The Matriks Biotek shikari Antibody to Infliximab ELISA Kit can be efficiently used for monitoring anti-Infliximab antibodies during therapy and offers the clinician a tool for decision
on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Infliximab antibodies.

USE YOUR DRUG EFFECTIVELY AND SAFELY

Check anti-infliximab antibodies in your patients sera with Q-ATI, escalate the dose or combine with (e.g.) methotrexate when needed.

Total and Free Antibody to Infliximab (Remicade®) ELISA

Enzyme immunoassay for the semi-quantitative determination (screening) of total and free antibodies to infliximab in serum and plasma.

Free and Total Anti drug Antibody monitoring gained high importance along with measuring free drug from
the patient samples. In order to make these measurements simple yet more informative. We have produced
SHIKARI® Q-ATI DUO to measure Free and Total anti drug antibodies to Infliximab simultaniously on the same plate.
The kit is semi-quantitative and enables follow up of the patients to adjust the dose of the drug and/or frequency
of administration

If quantitative and confirmation is needed please refer to SHIKARI® Q-ATIv6.